In a severe carbapenem‑resistant Gram‑negative infection suspected of producing a metallo‑β‑lactamase, is aztreonam plus ceftazidime‑avibactam (Zerbaxa) preferable to ceftazidime‑avibactam alone (Zavicefta)?

Aztreonam + Ceftazidime-Avibactam (Zavicefta) is Superior for Metallo-β-Lactamase Infections

For severe carbapenem-resistant Gram-negative infections suspected or confirmed to produce metallo-β-lactamases (MBLs), use aztreonam combined with ceftazidime-avibactam (Zavicefta). This combination is the preferred regimen over ceftazidime-avibactam alone, which has no activity against MBL-producing organisms.

Critical Clarification: Zerbaxa vs Zavicefta

Your question contains a critical error: Zerbaxa is NOT ceftazidime-avibactam. Zerbaxa is ceftolozane-tazobactam, a completely different drug with no activity against MBL producers 1. The FDA label explicitly states that Zerbaxa "is not active against bacteria that produce serine carbapenemases [K. pneumoniae carbapenemase (KPC)], and metallo-beta-lactamases" 1.

Zavicefta (ceftazidime-avibactam) is the correct drug to combine with aztreonam for MBL infections.

Why This Combination Works

Mechanistic Rationale

• Aztreonam is stable against MBLs but is hydrolyzed by other β-lactamases (ESBLs, AmpC) commonly co-produced by CRE 2
• Avibactam protects aztreonam from these non-MBL β-lactamases, restoring aztreonam's activity against the organism 2
• Ceftazidime-avibactam alone fails because avibactam does not inhibit metallo-β-lactamases 1, 3

Guideline Support

Both the 2022 ESCMID guidelines 4 and 2023 Asian guidelines 2 provide conditional recommendations for this combination:

• "For patients with severe infections caused by CRE carrying metallo-β-lactamases... we suggest aztreonam and ceftazidime-avibactam combination therapy" 4 (Conditional recommendation, Moderate quality evidence)

• "Ceftazidime-avibactam combined with aztreonam is suggested as a preferential choice over other antimicrobial therapies for the treatment of infections caused by metallo-β-lactamases-producing CRE" 2 (Weak recommendation, very low-quality evidence)

Clinical Outcomes Data

The most compelling evidence comes from prospective studies showing substantial mortality reduction 2:

• 30-day mortality: 19.2% with ceftazidime-avibactam + aztreonam vs 44% with other active agents (p=0.007)
• Hazard ratio for mortality: 0.37 (95% CI 0.13-0.74)
• Clinical failure rate reduced by 70%: HR 0.30 (95% CI 0.14-0.65)
• Shorter hospital stay: HR 0.49 (95% CI 0.82)

When to Use This Combination

Mandatory Indications

1. Confirmed MBL production (NDM, VIM, IMP genes detected)
2. Severe infection with suspected MBL based on:
   • Geographic epidemiology (high NDM prevalence regions)
   • Prior MBL colonization/infection
   • Resistance to ceftazidime-avibactam alone

Critical Implementation Steps

Before starting therapy:

• Identify carbapenemase type whenever possible 2
• If MBL is confirmed or highly suspected → use combination
• If only KPC or OXA-48 → ceftazidime-avibactam alone may suffice 2

Dosing considerations:

• Administer aztreonam and ceftazidime-avibactam simultaneously to ensure synchronized drug exposure 5, 6
• Adjust both agents for renal function independently 6
• Standard dosing: Ceftazidime-avibactam 2.5g IV q8h + Aztreonam 2g IV q8h

Common Pitfalls to Avoid

1. Don't confuse Zerbaxa with Zavicefta - they are completely different drugs with different spectra
2. Don't use ceftazidime-avibactam alone for MBL infections - it will fail 1, 3
3. Don't assume synergy without testing - while most isolates show synergy (96-98%), some don't 7, 8
4. Don't forget renal dose adjustments - both drugs require independent adjustment 6

Strength of Evidence Limitations

While guidelines support this combination, the evidence quality is very low to moderate 4, 2. The mortality benefit comes from observational studies, not randomized trials. However, given:

• The mechanistic rationale is sound
• In vitro synergy is consistently demonstrated 2, 3, 7
• Alternative options are extremely limited
• Mortality differences are substantial (>20% absolute reduction)

The combination remains the best available option for MBL-producing CRE infections despite imperfect evidence.

Alternative Considerations

If ceftazidime-avibactam + aztreonam is unavailable:

• Cefiderocol may be considered, though recent data suggest caution in CRAB infections 4
• Aztreonam-avibactam (fixed combination) shows promise but availability is limited 5, 9, 3